PRESS RELEASES

Featured post

June 01, 2023

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK^® CERTIFICATION^™

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK CERTIFICATION

Read more »

Featured post

May 26, 2023

Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing at ASCO^® 2023

Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing At ASCO® 2023

Read more »

Featured post

May 17, 2023

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

Read more »

December 06, 2022

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS^® 2022
November 03, 2022

Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability
October 24, 2022

Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting
September 22, 2022

Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations
September 10, 2022

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress
August 02, 2022

Exact Sciences Announces Second Quarter 2022 Results
August 02, 2022

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients
July 08, 2022

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy
June 01, 2022

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022
May 19, 2022

Exact Sciences at DDW 2022
May 11, 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients
April 28, 2022

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Choose your country or region:

PRESS RELEASES

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK^® CERTIFICATION^™

Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing at ASCO^® 2023

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS^® 2022

Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability

Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting

Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

Exact Sciences Announces Second Quarter 2022 Results

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Multimedia

Quick Links

Choose your country or region:

PRESS RELEASES

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATION™

Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing at ASCO® 2023

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability

Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting

Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

Exact Sciences Announces Second Quarter 2022 Results

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX® GPS™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Multimedia

Quick Links

Follow us on

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK^® CERTIFICATION^™

Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing at ASCO^® 2023

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS^® 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients